Gene:
CYP2C9
cytochrome P450, family 2, subfamily C, polypeptide 9

Available Prescribing Info

Dosing Guidelines
  1. CPIC Guideline for phenytoin and CYP2C9,HLA-B
  2. CPIC Guideline for warfarin and CYP2C9,VKORC1
  3. DPWG Guideline for acenocoumarol and CYP2C9
  4. DPWG Guideline for glibenclamide and CYP2C9
  5. DPWG Guideline for gliclazide and CYP2C9
  6. DPWG Guideline for glimepiride and CYP2C9
  7. DPWG Guideline for phenprocoumon and CYP2C9
  8. DPWG Guideline for phenytoin and CYP2C9
  9. DPWG Guideline for tolbutamide and CYP2C9
last updated 08/05/2014

1. CPIC Guideline for phenytoin and CYP2C9,HLA-B

Summary

Phenytoin is contraindicated in individuals with the HLA-B*15:02 variant allele ("HLA-B*15:02-positive") due to significantly increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Additionally, patients with the CYP2C9 poor metabolizer phenotype may require reduced doses of phenytoin.

There's more of this guideline. Read more.



last updated 08/10/2011

3. DPWG Guideline for acenocoumarol and CYP2C9

Summary

Check INR more frequently after initiating or discontinuing NSAIDs in individuals taking acenocoumarol with at least one CYP2C9 *2 or *3 allele.

There's more of this guideline. Read more.






last updated 08/10/2011

8. DPWG Guideline for phenytoin and CYP2C9

Summary

Use the standard starting dose of phenytoin and reduce the maintenance dose based on CYP2C9 genotype; monitor response and serum concentrations and be aware of ADEs.

There's more of this guideline. Read more.




Annotated Labels

  1. FDA Label for celecoxib and CYP2C9
  2. FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6
  3. FDA Label for flurbiprofen and CYP2C9
  4. FDA Label for lesinurad and CYP2C9
  5. FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B
  6. FDA Label for prasugrel and CYP2B6,CYP2C19,CYP2C9,CYP3A5
  7. FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1
  8. EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4
  9. PMDA Label for celecoxib and CYP2C9
  10. HCSC Label for celecoxib and CYP2C9
  11. HCSC Label for warfarin and CYP2C9,VKORC1

last updated 10/25/2013

1. FDA Label for celecoxib and CYP2C9

Actionable PGx

Summary

Celecoxib is metabolized primarily by CYP2C9. Patients who are known or suspected to be poor CYP2C9 metabolizers should be administered celecoxib with caution. Consider a dose reduction by 50% (or alternative management for juvenile rheumatoid arthritis (JRA)) in patients who are known or suspected to be CYP2C9 poor metabolizers.

There's more of this label. Read more.


2. FDA Label for flibanserin and CYP2C19,CYP2C9,CYP2D6

Actionable PGx

Summary

The FDA-approved drug label for flibanserin (ADDYI) states that poor metabolizers of CYP2C19 had increased exposure to the drug as compared to extensive metabolizers. One subject who was a poor metabolizer experienced syncope. The label also notes the influence of CYP2D6 and CYP2C9 on flibanserin exposure.

There's more of this label. Read more.


last updated 10/25/2013

3. FDA Label for flurbiprofen and CYP2C9

Informative PGx

Summary

In vitro studies have demonstrated that cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen. CYP2C9 poor metabolizers should be administered flurbiprofen with caution due to the possibility of high plasma levels resulting from decreased clearance.

There's more of this label. Read more.



last updated 10/25/2013

5. FDA Label for phenytoin and CYP2C19,CYP2C9,HLA-B

Actionable PGx

Summary

A strong association between the risk of developing SJS/TEN and the presence of HLA-B*1502, an inherited allelic variant of the HLA B gene, in patients using carbamazepine. Limited evidence suggests that HLAB*1502 may be a risk factor for the development of SJS/TEN in patients of Asian ancestry taking other antiepileptic drugs associated with SJS/TEN, including phenytoin. Consideration should be given to avoiding phenytoin as an alternative for carbamazepine in patients positive for HLA-B*1502.

There's more of this label. Read more.



last updated 07/14/2014

7. FDA Label for warfarin and CYP2C9,PROC,PROS1,VKORC1

Actionable PGx

Summary

Warfarin (Coumadin) is an anticoagulant used as a prophylaxis and to treat venous thrombosis, pulmonary embolism, thromboembolic complications from atrial fibrillationa and cardiac valve replacement, and to reduce the recurrence of myocardial infarction. Pharmacogenomics-related dosing information for CYP2C9 and VKORC1 variants is provided within the label. The drug label notes that deficiency in protein C (PROC) or protein S (PROS1) have been associated with tissue necrosis following warfarin administration.

There's more of this label. Read more.


last updated 08/06/2014

8. EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

There's more of this label. Read more.


9. PMDA Label for celecoxib and CYP2C9

Actionable PGx

Summary

The PMDA package insert for celecoxib (Celecox) notes that individuals with the CYP2C9 *1/*3 or *3/*3 genotypes had increased AUC or Cmax of celecoxib as compared to those with the *1/*1 genotype.

There's more of this label. Read more.


10. HCSC Label for celecoxib and CYP2C9

Actionable PGx

Summary

The product monograph for celecoxib (CELEBREX) notes that patients who are CYP2C9 poor metabolizers should be administered celecoxib with caution. It further states that the drug should be introduced at half the lowest recommended dose in these individuals, with a maximum recommended dose of 100 mg/day. However, the product monograph does not discuss CYP2C9 genotyping prior to treatment.

There's more of this label. Read more.


11. HCSC Label for warfarin and CYP2C9,VKORC1

Actionable PGx

Summary

The product monograph for warfarin (COUMADIN) notes that patients carrying one or two copies of the CYP2C9*2 or *3 alleles may require a decreased mean daily warfarin dose, and have an increased bleeding risk, as compared to those homozygous for the CYP2C9*1 allele. Additionally, variations in the VKORC1 gene, such as -1639G>A, are also associated with changes in the dose requirement of warfarin.

There's more of this label. Read more.


Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below. Please follow the link in the "Position" column for more information about a particular variant. Each link in the "Position" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for CYP2C9

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA *1 N/A N/A N/A
No VIP available CA VA *2 N/A N/A N/A
No VIP available CA VA *3 N/A N/A N/A
No VIP available No VIP available VA *4 N/A N/A N/A
No VIP available CA VA *5 N/A N/A N/A
No VIP available CA VA *6 N/A N/A N/A
No VIP available CA VA *8 N/A N/A N/A
No VIP available No VIP available VA *9 N/A N/A N/A
No VIP available No VIP available VA *10 N/A N/A N/A
No VIP available CA VA *11 N/A N/A N/A
No VIP available No VIP available VA *12 N/A N/A N/A
No VIP available CA VA *13 N/A N/A N/A
No VIP available No VIP available VA *14 N/A N/A N/A
No VIP available No VIP available VA *17 N/A N/A N/A
No VIP available No VIP available VA *25 N/A N/A N/A
No VIP available No VIP available VA *30 N/A N/A N/A
No VIP available No VIP available VA *31 N/A N/A N/A
No VIP available No VIP available VA *32 N/A N/A N/A
No VIP available No VIP available VA *33 N/A N/A N/A
No VIP available No VIP available VA *57 N/A N/A N/A
No VIP available No VIP available VA *58 N/A N/A N/A
No VIP available CA VA *59 N/A N/A N/A
rs10509680 NC_000010.10:g.96734339G>T, NC_000010.11:g.94974582G>T, NG_008385.1:g.40925G>T, NM_000771.3:c.961+2337G>T, XM_005269575.1:c.961+2337G>T, rs45630770, rs45631363
G > T
SNP
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
rs12782374 NC_000010.10:g.96695351G>A, NC_000010.11:g.94935594G>A, NG_008385.1:g.1937G>A
G > A
SNP
rs141011391 NC_000010.10:g.96748733A>G, NC_000010.11:g.94988976A>G, NG_008385.1:g.55319A>G, NM_000771.3:c.1421A>G, NP_000762.2:p.Asn474Ser, XM_005269575.1:c.1275-490A>G
A > G
SNP
N474S
rs1799853 NC_000010.10:g.96702047C=, NC_000010.10:g.96702047C>T, NC_000010.11:g.94942290C=, NC_000010.11:g.94942290C>T, NG_008385.1:g.8633C=, NG_008385.1:g.8633C>T, NM_000771.3:c.430C=, NM_000771.3:c.430C>T, NP_000762.2:p.Arg144=, NP_000762.2:p.Arg144Cys, XM_005269575.1:c.430C=, XM_005269575.1:c.430C>T, XP_005269632.1:p.Arg144=, XP_005269632.1:p.Arg144Cys, rs17110268, rs28371674, rs33968134, rs60690363
C > T
SNP
R144C
rs1934969 NC_000010.10:g.96748495A>T, NC_000010.11:g.94988738A>T, NG_008385.1:g.55081A>T, NM_000771.3:c.1292-109A>T, XM_005269575.1:c.1275-728A>T, rs17522303, rs59299689
A > T
SNP
rs28371685 NC_000010.10:g.96740981C>T, NC_000010.11:g.94981224C>T, NG_008385.1:g.47567C>T, NM_000771.3:c.1003C>T, NP_000762.2:p.Arg335Trp, XM_005269575.1:c.1003C>T, XP_005269632.1:p.Arg335Trp, rs60219528
C > T
SNP
R335W
rs28371686 NC_000010.10:g.96741058C>G, NC_000010.11:g.94981301C>G, NG_008385.1:g.47644C>G, NM_000771.3:c.1080C>G, NP_000762.2:p.Asp360Glu, XM_005269575.1:c.1080C>G, XP_005269632.1:p.Asp360Glu, rs57527516
C > G
SNP
D360E
rs2860905 NC_000010.10:g.96702295G>A, NC_000010.11:g.94942538G>A, NG_008385.1:g.8881G>A, NM_000771.3:c.481+197G>A, XM_005269575.1:c.481+197G>A, rs56268370
G > A
SNP
rs4086116 NC_000010.10:g.96707202C>T, NC_000010.11:g.94947445C>T, NG_008385.1:g.13788C>T, NM_000771.3:c.482-334C>T, XM_005269575.1:c.482-334C>T, rs56627368, rs57822479
C > T
SNP
rs4917639 NC_000010.10:g.96725535A>C, NC_000010.11:g.94965778A>C, NG_008385.1:g.32121A>C, NM_000771.3:c.820-6326A>C, XM_005269575.1:c.820-6326A>C, rs17429632, rs56870279
A > C
SNP
rs4918758 NC_000010.10:g.96697252T>C, NC_000010.11:g.94937495T>C, NG_008385.1:g.3838T>C, NM_000771.3:c.-1188T>C, XM_005269575.1:c.-1188T>C, rs17110346
T > C
SNP
rs56165452 NC_000010.10:g.96741054T>C, NC_000010.11:g.94981297T>C, NG_008385.1:g.47640T>C, NM_000771.3:c.1076T>C, NP_000762.2:p.Ile359Thr, XM_005269575.1:c.1076T>C, XP_005269632.1:p.Ile359Thr
T > C
SNP
I359T
rs7089580 NC_000010.10:g.96705223A>T, NC_000010.11:g.94945466A>T, NG_008385.1:g.11809A>T, NM_000771.3:c.482-2313A>T, XM_005269575.1:c.482-2313A>T, rs111172059, rs58626010
A > T
SNP
rs71486745 NC_000010.10:g.96695776_96695777delGT, NC_000010.11:g.94936019_94936020delGT, NG_008385.1:g.2362_2363delGT
GT > -
indel
rs72558187 NC_000010.10:g.96701715T>C, NC_000010.11:g.94941958T>C, NG_008385.1:g.8301T>C, NM_000771.3:c.269T>C, NP_000762.2:p.Leu90Pro, XM_005269575.1:c.269T>C, XP_005269632.1:p.Leu90Pro, rs74052158
T > C
SNP
L90P
rs72558189 NC_000010.10:g.96701991G>A, NC_000010.11:g.94942234G>A, NG_008385.1:g.8577G>A, NM_000771.3:c.374G>A, NP_000762.2:p.Arg125His, XM_005269575.1:c.374G>A, XP_005269632.1:p.Arg125His, rs73994288
G > A
SNP
R125H
rs7900194 NC_000010.10:g.96702066G>A, NC_000010.11:g.94942309G>A, NG_008385.1:g.8652G>A, NM_000771.3:c.449G>A, NP_000762.2:p.Arg150His, XM_005269575.1:c.449G>A, XP_005269632.1:p.Arg150His, rs57530584
G > A
SNP
R150H
rs9332092
T > C
SNP
rs9332094 NC_000010.10:g.96696674T>C, NC_000010.11:g.94936917T>C, NG_008385.1:g.3260T>C, NM_000771.3:c.-1766T>C, XM_005269575.1:c.-1766T>C, rs61444591
T > C
SNP
rs9332096 NC_000010.10:g.96696875C>T, NC_000010.11:g.94937118C>T, NG_008385.1:g.3461C>T, NM_000771.3:c.-1565C>T, XM_005269575.1:c.-1565C>T
C > T
SNP
rs9332098
G > A
SNP
rs9332104 NC_000010.10:g.96698690T>C, NC_000010.11:g.94938933T>C, NG_008385.1:g.5276T>C, NM_000771.3:c.168+83T>C, XM_005269575.1:c.168+83T>C, rs58097354
T > C
SNP
rs9332120 NC_000010.10:g.96701850T>C, NC_000010.11:g.94942093T>C, NG_008385.1:g.8436T>C, NM_000771.3:c.331+73T>C, XM_005269575.1:c.331+73T>C
T > C
SNP
rs9332127 NC_000010.10:g.96707471G>C, NC_000010.11:g.94947714G>C, NG_008385.1:g.14057G>C, NM_000771.3:c.482-65G>C, XM_005269575.1:c.482-65G>C, rs17847038, rs58304507
G > C
SNP
rs9332131 NC_000010.10:g.96709039delA, NC_000010.11:g.94949282delA, NG_008385.1:g.15625delA, NM_000771.3:c.817delA, NP_000762.2:p.Lys273Argfs, XM_005269575.1:c.817delA, XP_005269632.1:p.Lys273Argfs
A > -
indel
K273R
rs9332174 NC_000010.10:g.96732097A>G, NC_000010.11:g.94972340A>G, NG_008385.1:g.38683A>G, NM_000771.3:c.961+95A>G, XM_005269575.1:c.961+95A>G, rs17521927, rs60502756
A > G
SNP
rs9332197 NC_000010.10:g.96740908T>C, NC_000010.11:g.94981151T>C, NG_008385.1:g.47494T>C, NM_000771.3:c.962-32T>C, XM_005269575.1:c.962-32T>C, rs60905497
T > C
SNP
rs9332238 NC_000010.10:g.96748492G>A, NC_000010.11:g.94988735G>A, NG_008385.1:g.55078G>A, NM_000771.3:c.1292-112G>A, XM_005269575.1:c.1275-731G>A
G > A
SNP
rs9332239 NC_000010.10:g.96748777C>T, NC_000010.11:g.94989020C>T, NG_008385.1:g.55363C>T, NM_000771.3:c.1465C>T, NP_000762.2:p.Pro489Ser, XM_005269575.1:c.1275-446C>T, rs59029001
C > T
SNP
P489S
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  CYP2C10
Alternate Symbols:  P450IIC9
PharmGKB Accession Id: PA126

Details

Cytogenetic Location: chr10 : q23.33 - q23.33
GP mRNA Boundary: chr10 : 96698350 - 96749486
GP Gene Boundary: chr10 : 96688350 - 96752486
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

CYP2C9 is a phase I drug-metabolizing cytochrome P450 (CYP450) enzyme isoform that plays a major role in the oxidation of both xenobiotic and endogenous compounds. Gray et al. [Article:8530044] identified CYP2C9 as one of several CYP2C genes clustered in a 500kb region on chromosome 10q24. The cluster comprises four genes arranged in the order CYP2C8-CYP2C9-CYP2C19-CYP2C18 [Article:8530044]. Several studies identified a single nucleotide polymorphism (SNP) linkage between the CYP2C8 and CYP2C9 genes [Articles:8530044, 12435384, 19381162]. CYP2C9 is primarily expressed in the liver, and the expression level is reported to be the second highest among CYP isoforms [Article:12580989]. Only the CYP enzyme CYP3A4 is quantitatively more highly expressed in human liver [Article:15822186]. It has been estimated that CYP2C9 is responsible for the metabolic clearance of up to 15%-20% of all drugs undergoing Phase I metabolism [Articles:19152219, 11927841].

Inducer and Inhibitors: CYP2C9 is induced by rifampicin [Article:19369937]. Treatment with rifampicin has been shown consistently to increase the clearance of drugs eliminated by CYP2C9. The clearance of losartan, phenytoin, tolbutamide and S-warfarin is approximately doubled in healthy volunteers or patients treated with rifampicin [Articles:9663807, 18650803]. CYP2C9 is inhibited by amiodarone, fluconazole, and sulphaphenazole among other drugs [Article:9663807]. Dangerous drug-drug interaction can arise when an inhibitor such as one of these is added to a therapeutic regime that include drugs with a low therapeutic index, such as S-warfarin, tolbutamine, and phenytoin [Articles:7944078, 8806399, 15963007]. For example, there are numerous studies documenting potentiation of the anticoagulant effect of warfarin in patients coadministered with amiodarone [Articles:18463344, 14677664, 1563209].

Structure: CYP2C9 is the enzyme responsible for the metabolism of the S-isomer of warfarin that is principally responsible for the anticoagulant effect of the drug. The crystal structure of human CYP2C9 was described by Williams et al. [Article:12861225], for both CYP2C9 in complex with warfarin and unliganded CYP2C9 (Protein Data Bank ID: 1OG2 and 1OG5, respectively). The structure showed unanticipated interactions between CYP2C9 and warfarin, revealing a new binding pocket, suggesting that CYP2C9 may simultaneously accommodate multiple ligands during its biologic function [Article:12861225]. Structural analysis suggested that CYP2C9 may undergo an allosteric change when binding warfarin [Article:12861225]. An X-ray crystal structure of CYP2C9, in complex with the NSAID flurbiprofen, has also been described (Protein Data Bank ID: 1R9O) [Article:15181000].

Genetic phenotypes and adverse drug reactions (ADR): The gene coding for the CYP2C9 enzyme is highly polymorphic, including functional variants of major pharmacogenetic importance. Changes in metabolic activity caused by genetic variants in CYP2C9 play a major role in pathogenesis due to ADRs. Patients with low enzyme activity are at risk of ADR, especially for CYP2C9 substrates with a narrow therapeutic window, such as S-warfarin, phenytoin, glipizide, and tolbutamide [Article:14511900]. A large body of literature investigates two common non-synonymous variants within CYP2C9 (R144C, [rs1799853] and I359L, [rs1057910]), leading to poor metabolism phenotypes. Both variants have significantly lower frequencies in African and Asian populations compared to Caucasian populations [Articles:11927841, 19151603], see frequency tables under Important variants. Individuals with these variants are at risk of prolonged bleeding time and increased incidence of severe bleeding in warfarin therapy [Article:10073515], higher possibility of low blood sugar levels during glipizide and tolbutamide therapy [Article:10208645], and more frequent symptoms of overdose in phenytoin therapy [Article:10774639]. Patients with the poor metabolizer *2 (identified by R144C) and *3 (identified by I359L) haplotypes require lower doses of warfarin to achieve a similar anticoagulant as patients with at least one *1 (wild-type) haplotype [Articles:10073515, 19031075]. However, it is now known that CYP2C9 genotype accounts for only part of the variability in warfarin sensitivity [Articles:11893129, 12621390] because VKORC1 genotype, age, and weight are also key factors in predicting the therapeutic dose for warfarin [Article:16424822]. CYP2C9 is responsible for about 90% of phenytoin metabolism, and the CYP2C9*2 and *3 haplotypes decrease the metabolism of phenytoin [Articles:19258521, 16873909, 11434505].

Besides the two variants mentioned above, a large number of SNPs have been described in the regulatory and coding regions of the CYP2C9 gene (http://www.cypalleles.ki.se/cyp2c9.htm). Some of the polymorphisms are associated with reduced enzyme activity compared to wild-type in in-vitro experiments; only a few enzyme experiments have been done in-vivo. CYP2C9*6 (818delA, rs933213) is a rare (1 allele in 158 African Americans, 0 in Caucasians) null allele with lack of activity due to a splicing mutation that causes a frameshift resulting in a truncated protein [Article:11740344]. The variant I359T (CYP2C*4) is also a rare (0.5% in African Americans, 6% in Caucasians) polymorphism [Articles:8873220, 9631918]. Both have been detected in patients who had adverse reactions to phenytoin [Articles:11740344, 10739176]. CYP2C9*5 (D360E, rs28371683), *6, *8 (R150H, rs7900194) and *11 (R335W, rs28371685) variants were associated with decreased phenytoin metabolism in a black population [Article:16220110]. The CYP2C9 promoter contains important regulatory elements: two HNF4 sites, a nuclear receptor pregnane X receptor binding site, a constitutive androstane receptor (CAR)/PXR site, and a glucocorticoid responsive element [Articles:15919766, 12181452, 11678789]. There have been multiple polymorphisms detected in the 5' untranslated region of CYP2C9 but these have not yet been shown to contribute to response to warfarin [Articles:15900281, 16513444] or phenytoin [Article:11434505] in-vivo, beyond those which appear to be in linkage disequilibrium with known exonic variants [Articles:15900281, 15070684, 11503012]. A recent paper investigating 22 known and 9 novel promoter SNPs with an in-vitro promoter activity assay suggests that genetic variation within CYP2C9 regulatory sequences is likely to contribute to differences in CYP2C9 phenotype, both within and among different populations, independent from known exonic variants [Article:18310303].

Citation Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and genomics. 2010. Van Booven Derek, Marsh Sharon, McLeod Howard, Carrillo Michelle Whirl, Sangkuhl Katrin, Klein Teri E, Altman Russ B. PubMed
History

Submitted by Derek Van Booven (CREATE), Sharon Marsh, Howard McLeod (CREATE), Michelle Whirl Carrillo, Katrin Sangkuhl

Key Publications
  1. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochimica et biophysica acta. 2007. Kirchheiner Julia, Seeringer Angela. PubMed
  2. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clinical pharmacology and therapeutics. 2005. Kirchheiner Julia, Brockmöller Jürgen. PubMed
  3. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same?. Drug metabolism and disposition: the biological fate of chemicals. 2005. Rodrigues A David. PubMed
  4. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. European journal of clinical pharmacology. 2003. Griskevicius Laimonas, Yasar Umit, Sandberg Mia, Hidestrand Mats, Eliasson Erik, Tybring Gunnel, Hassan Moustapha, Dahl Marja-Liisa. PubMed
  5. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics. 2003. Kirchheiner Julia, Störmer Elke, Meisel Christian, Steinbach Nadine, Roots Ivar, Brockmöller Jürgen. PubMed
  6. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA : the journal of the American Medical Association. 2002. Higashi Mitchell K, Veenstra David L, Kondo L Midori, Wittkowsky Ann K, Srinouanprachanh Sengkeo L, Farin Fred M, Rettie Allan E. PubMed
  7. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999. Aithal G P, Day C P, Kesteven P J, Daly A K. PubMed
  8. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. British journal of clinical pharmacology. 1998. Miners J O, Birkett D J. PubMed
  9. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics. 1995. Gray I C, Nobile C, Muresu R, Ford S, Spurr N K. PubMed
Variant Summaries rs1057910, rs1799853
Haplotype Summaries CYP2C9*2, CYP2C9*3
Drugs
Pathways

Haplotype Overview

Haplotypes in the "CYP2C9 Cytochrome P450 Nomenclature DB Haplotype Set" are derived from the Human Cytochrome P450 (CYP) Allele Nomenclature Database. The Human Cytochrome P450 (CYP) Allele Nomenclature Database states that nucleotide changes listed below are based on NCBI Reference Sequence M61857.1. Note that the nucleotide positions from the Human Cytochrome P450 (CYP) Allele Nomenclature Database do not directly match the given NCBI reference sequence; rather nucleotide base numbering appears to start at position 11 in the sequence file (ATG start codon). For questions about nucleotide positions, please contact the Human Cytochrome P450 (CYP) Allele Nomenclature Database directly, as they are the authoritative source on cytochrome P450 nomenclature.

Haplotypes in the "CPIC CYP2C9 Haplotype Set" are derived from the supplemental tables in the CPIC guidelines regarding CYP2C9.

Last updated 7/24/15.

Source: PharmGKB

CPIC CYP2C9 Haplotype Set

CYP2C9 Cytochrome P450 Nomenclature DB Haplotype Set

All alleles in the download file are on the positive chromosomal strand. PharmGKB considers the first haplotype listed in each table as the reference haplotype for that set.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Anti-diabetic Drug Nateglinide Pathway, Pharmacokinetics
    Nateglinide metabolism and transport in liver cell
  1. Atorvastatin/Lovastatin/Simvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Caffeine Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of caffeine.
  1. Celecoxib Pathway, Pharmacokinetics
    Schematic representation of celecoxib metabolism in human liver cell.
  1. Clopidogrel Pathway, Pharmacokinetics
    Representation of genes involved in metabolism of clopidogrel.
  1. Cyclophosphamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of cyclophosphamide.
  1. Doxepin Pathway, Pharmacokinetics
    Stylized liver cell showing candidate genes involved in the metabolism of the tricyclic doxepin.
  1. Fluoxetine Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of fluoxetine.
  1. Fluvastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.
  1. Gefitinib Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the transportation and metabolism of gefitinib.
  1. Ibuprofen Pathway, Pharmacokinetics
    Stylized diagram of metabolism and transport of ibuprofen in the liver and kidney.
  1. Ifosfamide Pathway, Pharmacokinetics
    Model human liver cell showing genes involved in the metabolism of ifosfamide.
  1. Losartan Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of losartan.
  1. Nevirapine Pathway, Pharmacokinetics
    Representation of candidate genes involved in biotransformation of nevirapine and its mechanism of action in an infected liver cell.
  1. Phenytoin Pathway, Pharmacokinetics
    Genes involved in the metabolism of phenytoin in the human liver cell.
  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.
  1. Rosiglitazone Pathway, Pharmacokinetics
    Rosiglitazone is transported from hepatic sinusoids into hepatocytes -- a process mediated by the organic anion transporting polypeptide, where is is metabolized by cytochrome p450 2C8 and 2C9.
  1. Sorafenib Pharmacokinetics
    Schematic representation of sorafenib metabolism in human liver cell.
  1. Statin Pathway - Generalized, Pharmacokinetics
    Representation of the superset of all genes involved in the transport, metabolism and clearance of statin class drugs.
  1. Tamoxifen Pathway, Pharmacokinetics
    Diagram showing candidate genes for tamoxifen metabolism in the liver.
  1. Valproic Acid Pathway, Pharmacokinetics
    Graphic representation of the candidate genes involved in valproic acid pharmacokinetics.
  1. Warfarin Pathway, Pharmacokinetics
    Representation of the candidate genes involved in transport, metabolism and clearance of warfarin.
  1. Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics
    Representation of candidate genes involved in the metabolism of zidovudine and its mechanism of antiviral action.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
APOE
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP4F2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GGCX
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
VKORC1

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
1,7-dimethylxanthine
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
4-hydroxytamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abacavir
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
abiraterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acarbose
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aceclofenac
DG No Drug Label available CA VA No VIP available No VIP available
acenocoumarol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
acetaminophen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alemtuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alfentanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
allopurinol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
almotriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
alprazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aminophenazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amiodarone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amitriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amlodipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amodiaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amphetamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
amphotericin b
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
anastrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aripiprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
arsenic trioxide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
aspirin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
atenolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
atomoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
atorvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
azapropazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
azathioprine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
aztreonam
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
belinostat
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
benzbromarone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
benztropine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
boceprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
bosentan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
brivaracetam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
buprenorphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
bupropion
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
buspirone
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
busulfan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cabozantinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
caffeine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
capecitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carbamazepine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
carisoprodol
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
carvedilol
celecoxib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ceritinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cerivastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cetuximab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cevimeline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chloramphenicol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorcycloguanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chloroquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorpheniramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorpromazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorpropamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
chlorzoxazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cholestyramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cimetidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ciprofloxacin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
citalopram
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clarithromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clindamycin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clobazam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clofibrate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clomipramine
clopidogrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clotrimazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
clozapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
codeine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
coumarin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
crizotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyclobenzaprine
cyclophosphamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyclosporine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
cyproheptadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dabigatran
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dabrafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
danazol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dapsone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dasatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
daunorubicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
debrisoquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
desflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
desipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexamethasone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dexlansoprazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dextromethorphan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diatrizoate
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
diazepam
diclofenac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dienestrol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
digoxin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diltiazem
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
diphenhydramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
docetaxel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
donepezil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
dopamine
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
doxepin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
doxorubicin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
drospirenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
duloxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
efavirenz
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eletriptan
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eltrombopag
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
endoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
enflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
entacapone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
epirubicin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
erlotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
erythromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
escitalopram
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
esomeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
eszopiclone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ethambutol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ethinyl estradiol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
etodolac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
etoposide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
exemestane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ezetimibe
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
felodipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fenofibrate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fentanyl
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flecainide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flibanserin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flucloxacillin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
fluindione
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flunarizine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flunitrazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluorouracil
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
fluoxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluphenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
flurazepam
No Dosing Guideline available DL CA VA No VIP available No VIP available
flurbiprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluticasone propionate
fluvastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fluvoxamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
frovatriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
fulvestrant
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
furafylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
furosemide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
galantamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
gefitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemcitabine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemfibrozil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
gemtuzumab ozogamicin
glibenclamide
DG No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
gliclazide
glimepiride
glipizide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
gliquidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
glucosamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
glucose
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
grapefruit juice
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
haloperidol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
halothane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydralazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydrochlorothiazide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydrocodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydromorphone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
hydroxyzine
ibuprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ifosfamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
iloperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
imatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
imipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indacaterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
indinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
indomethacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
interferon alfa-2a, recombinant
irbesartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
irinotecan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isoflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
isoniazid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isotretinoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
isradipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
itraconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ivacaftor / lumacaftor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ketamine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ketoconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ketoprofen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
labetalol
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lacosamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lamivudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lamotrigine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lansoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lapatinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lenalidomide
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lesinurad
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
letrozole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levofloxacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
levothyroxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lisinopril
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lopinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
loratadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
lorazepam
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
lornoxicam
losartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
lovastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
maraviroc
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
marinol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
medroxyprogesterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mefenamic acid
meloxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
meperidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mephenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mercaptopurine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metformin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
methadone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methotrexate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
methylcholanthrene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metoclopramide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
metoprolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
miconazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
midazolam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mirtazapine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
modafinil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
montelukast
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
morphine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
moxifloxacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
mycophenolate mofetil
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
n-desmethyltamoxifen
naproxen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naratriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
naringenin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available PW
nateglinide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nefazodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nelfinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
nevirapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
niacin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nicardipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nicotine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nifedipine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nilotinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nortriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Noscapine
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
olanzapine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
omeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxaliplatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxcarbazepine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
oxycodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pamidronate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
panitumumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pantoprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
paroxetine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
peginterferon alfa-2a
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
peginterferon alfa-2b
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pentoxifylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
perphenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pertuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenobarbital
DG No Drug Label available CA VA No VIP available No VIP available
phenprocoumon
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
phenylbutazone
phenytoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pimozide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pioglitazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
piroxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pitavastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
posaconazole
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
prasugrel
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
pravastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prednisone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
primaquine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
probenecid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
procainamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
prochlorperazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
progesterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
proguanil
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
promethazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propafenone
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
propofol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propoxyphene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
propranolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
protriptyline
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
pyrazinamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quetiapine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinidine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
quinine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rabeprazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ramipril
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ranolazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rasburicase
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
regorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
repaglinide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
reserpine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ribavirin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
rifampin
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
risperidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ritonavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
rofecoxib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
rosiglitazone
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
rosuvastatin
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ruxolitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
salmeterol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
saquinavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
sertraline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sevoflurane
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sibutramine
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sildenafil
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
simvastatin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sirolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
SN-38
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
sorafenib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
st. john's wort
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
sulfamethoxazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulfaphenazole
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sulindac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
sunitinib
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tacrine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tacrolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tadalafil
tamoxifen
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tamsulosin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tegafur
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telaprevir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telithromycin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
telmisartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
temazepam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
temsirolimus
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
teniposide
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
tenoxicam
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terazosin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terbinafine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
terfenadine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
testosterone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tetrabenazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tetracycline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
theophylline
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioguanine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thioridazine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thiotepa
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ticagrelor
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ticlopidine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
timolol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tiotropium
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tipranavir
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tizanidine
tolbutamide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolcapone
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tolterodine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
torasemide
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
toremifene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tramadol
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tranilast
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tranylcypromine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trastuzumab
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trazodone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tretinoin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
triamterene
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
trimethoprim
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
trimipramine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
troglitazone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
troleandomycin
No Dosing Guideline available No Drug Label available CA VA No VIP available PW
valproic acid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
valsartan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vemurafenib
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
venlafaxine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
verapamil
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
voriconazole
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
vortioxetine
warfarin
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
zafirlukast
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
zidovudine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ziprasidone
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zoledronate
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zolmitriptan
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zolpidem
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
zuclopenthixol

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Acute coronary syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Adenoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Agranulocytosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Alcoholism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alzheimer Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Anemia, Sickle Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmias, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arterial Occlusive Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Rheumatoid
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Atrial Fibrillation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial Flutter
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Attention Deficit Disorder with Hyperactivity
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood Coagulation Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Brugada syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiomyopathy, Hypertrophic
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cardiovascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carotid Artery Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colonic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Coronary Artery Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coronary Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crigler-Najjar Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crohn Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystic Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Death
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Death, Sudden, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Depression
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Depressive Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Depressive Disorder, Major
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Diabetes Mellitus
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Diabetes Mellitus, Type 2
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interaction with drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
drug reaction with eosinophilia and systemic symptoms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Resistance
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
drug-induced liver injury
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Epidermal Necrolysis, Toxic
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophagitis
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Essential hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gastritis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gastrointestinal Hemorrhage
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Stromal Tumors
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gilbert's syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gingival Hyperplasia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Graft vs Host Disease
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Heart Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Heart Valve Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
heart valve replacement
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hematoma, Subdural
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
hemoglobin ss disease with vasoocclusive crisis
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
hemopoietic stem cell transplant
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hemorrhage
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hepatitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
HIV
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hodgkin Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperbilirubinemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperbilirubinemia, Hereditary
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypereosinophilic Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperlipoproteinemia Type II
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypertension, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperthyroidism
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hypoglycemia
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hypotension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypothyroidism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammatory Bowel Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Kidney Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leishmaniasis, Visceral
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Lymphocytic, Chronic, B-Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Nonlymphocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Promyelocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Leukopenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long QT Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lung Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Maculopapular Exanthema
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Mental Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Migraine without Aura
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Muscular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myelodysplastic Syndromes
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Myocardial Infarction
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myopathy, Central Core
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Necrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasm Metastasis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nephrotoxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ocular Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Osteonecrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ovarian Failure, Premature
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
over-anticoagulation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Parkinson Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peripheral Vascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
platelet aggregation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pregnancy
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Psychotic Disorders
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Disease, Chronic Obstructive
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pulmonary Embolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Recurrence
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rhabdomyolysis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Rheumatic Heart Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
severe cutaneous adverse reactions
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sjogren's Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Stevens-Johnson Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stomach Neoplasms
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sudden Infant Death
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
tardive dyskinesia
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thromboembolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
thrombolytic disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thrombosis of cerebral veins
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Thyrotoxicosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time above therapeutic range
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time below therapeutic range
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time in therapeutic range
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time to achieve stable dose
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
time to therapeutic inr
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Torsades de Pointes
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Toxic liver disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tremor
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Tuberculosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tuberculosis, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor Lysis Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary Incontinence
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Vasculitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
venous thromboembolism
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Venous Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ventricular Fibrillation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Wegener Granulomatosis

Publications related to CYP2C9: 722

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite. Archives of pharmacal research. 2016. Kim Se-Hyung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population. Omics : a journal of integrative biology. 2016. De Andrés Fernando, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting prolonged dose titration in patients starting warfarin. Pharmacoepidemiology and drug safety. 2016. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia. Pharmacogenomics. 2016. Mosikian Anna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Theory based PKPD of S- and R-warfarin and effects on INR: influence of body size, composition and genotype in cardiac surgery patients. British journal of clinical pharmacology. 2016. Xue Ling, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico. Pharmacogenomics. 2016. Sánchez-Pozos Katy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets. Pharmacogenomics. 2016. Sivadas Ambily, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. Cardiovascular therapeutics. 2016. Zhang Jinhua, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data. European journal of clinical pharmacology. 2016. Smith R L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery. 2016. Brehm Kerstin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese. European journal of clinical pharmacology. 2016. Zeng Wu-Tao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of neuro-fuzzy model to explore gene-nutrient interactions modulating warfarin dose requirement. Pharmacogenomics. 2016. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics. 2016. Eriksson Niclas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR). Toxicology and applied pharmacology. 2016. Pourgholi Leyla, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast. Archives of pharmacal research. 2016. Lee Hyun-Jee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. Expert opinion on drug metabolism & toxicology. 2016. Tverdohleb Tatiana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exploring Variation in Known Pharmacogenetic Variants and its Association with Drug Response in Different Mexican Populations. Pharmaceutical research. 2016. Gonzalez-Covarrubias Vanessa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2016. Kalpana S R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of genome sequencing and clinical genotyping for pharmacogenes. Clinical pharmacology and therapeutics. 2016. Yang Wenjian, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2016. Na Gao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2016. Wypasek E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei medical journal. 2016. Cho Sun Mi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin Dosing Algorithms and the Need for Human Intervention. The American journal of medicine. 2016. Kasner Scott E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. Thrombosis and haemostasis. 2016. Shahabi Payman, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of pharmacogenomic VIP variants in Li nationality of southern China. Environmental toxicology and pharmacology. 2016. Ding Yipeng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. Journal of atherosclerosis and thrombosis. 2016. Yi Xingyang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Effect of Genetic Polymorphism on the Inhibition of Azole Antifungal Agents Against CYP2C9-Mediated Metabolism. Journal of pharmaceutical sciences. 2016. Niwa Toshiro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. The Journal of molecular diagnostics : JMD. 2016. Ji Yuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic or -epigenomic biomarkers in drug treatment - two sides of the same medal?. Clinical pharmacology and therapeutics. 2016. Ingelman-Sundberg Magnus, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery. 2016. González A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of Cytochrome P450 Enzymes in American Indian and Caucasian Children Admitted to a Psychiatric Hospital. Journal of child and adolescent psychopharmacology. 2016. McGrane Ian R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenetics and genomics. 2016. Tassaneeyakul Wichittra, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes. Pharmacogenomics. 2016. Schirmer Jan Henrik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users. Pharmacotherapy. 2016. Shendre Aditi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P-450 gene and drug interaction analysis in patients referred for pharmacogenetic testing. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016. Hocum Brian Thomas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population. Anatolian journal of cardiology. 2016. Dilge Taşkın Birce, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians. British journal of clinical pharmacology. 2016. Hasunuma Tomoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: A case-control study. Current clinical pharmacology. 2016. Thatte Urmila. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization. Pharmacogenomics. 2016. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics. 2016. Shah Rashmi R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. Cardiovascular therapeutics. 2015. An Sook Hee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol. Drug discoveries & therapeutics. 2016. Sehgal Tushar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism. Drug metabolism and disposition: the biological fate of chemicals. 2015. Tracy Timothy S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome medicine. 2016. Bourgeois Stephane, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adults. Indian journal of pharmacology. 2016. Sridharan Kannan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PloS one. 2016. Tong Hoi Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PloS one. 2016. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. PloS one. 2016. Berm Elizabeth J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis. Systematic reviews. 2016. Takeuchi Masanobu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prediction of Warfarin Dose in Pediatric Patients: An Evaluation of the Predictive Performance of Several Models. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG. 2016. Marek Elizabeth, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Integrated Patient and Tumor Genetic Testing for Individualized Cancer Therapy. Clinical pharmacology and therapeutics. 2015. Hertz Daniel L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotype-guided therapy improves initial acenocoumarol dosing. Results from a prospective randomised study. Thrombosis and haemostasis. 2015. Cerezo-Manchado Juan Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. Journal of human genetics. 2015. Jittikoon Jiraphun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management. Clinical and translational science. 2015. Jaja Cheedy, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. European journal of clinical pharmacology. 2015. Chung Jee-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery. Journal of thrombosis and haemostasis : JTH. 2015. Abohelaika S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association study of warfarin maintenance dose in a Brazilian sample. Pharmacogenomics. 2015. Parra Esteban J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Race influences warfarin dose changes associated with genetic factors. Blood. 2015. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration. Pharmacogenomics. 2015. Santos Paulo Caleb Junior Lima, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2015. Sermsathanasawadi Nuttawut, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clinic proceedings. 2015. Kaufman Amy L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy. The pharmacogenomics journal. 2015. Ortega-Vázquez A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke. Archives of medical research. 2015. Šupe Svjetlana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients. British journal of clinical pharmacology. 2015. Lanchote Vera Lucia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9*59. Drug metabolism and disposition: the biological fate of chemicals. 2015. Dai Da-Peng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID-Induced Gastropathy. Pain medicine (Malden, Mass.). 2015. Gupta Anita, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX. Pharmacogenetics and genomics. 2015. Fohner Alison E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Celecoxib pharmacogenetics and pediatric adenotonsillectomy: a double-blinded randomized controlled study. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2015. Murto Kimmo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials. Journal of cardiovascular pharmacology. 2015. Wang Zhi-Quan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiology and drug safety. 2015. Roth Joshua A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Individualized phenytoin therapy for Japanese pediatric patients with epilepsy based on CYP2C9 and CYP2C19 genotypes. Therapeutic drug monitoring. 2015. Yamamoto Yoshiaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomized controlled trials. Thrombosis research. 2015. Li Xiaoqi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Factors affecting time to maintenance dose in patients initiating warfarin. Pharmacoepidemiology and drug safety. 2015. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Factors influencing pharmacokinetics of warfarin in African-Americans: implications for pharmacogenetic dosing algorithms. Pharmacogenomics. 2015. Nagai Rui, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of dermatology in pharmacogenomics: drug-induced skin injury. Pharmacogenomics. 2015. Borroni Riccardo G. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Archives of pharmacal research. 2015. Lee Yun-Jeong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. European journal of clinical pharmacology. 2015. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2015. Wypasek Ewa, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of pharmacogenomic VIP variants in the lhoba population of southwest China. International journal of clinical and experimental pathology. 2015. He Yongjun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques. 2015. Jalil Nur Jalinna Abdul, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 Genes and the Therapeutic Warfarin Dose in Brazilian Patients with Thrombosis: A Prospective Cohort Study. Molecular diagnosis & therapy. 2014. de Oliveira Almeida Vanessa Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ibuprofen pathways. Pharmacogenetics and genomics. 2014. Mazaleuskaya Liudmila L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenetics and genomics. 2014. Drozda Katarzyna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. Pharmacogenomics. 2015. Li Xi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genotype and risk of major bleeding during warfarin treatment. Pharmacogenomics. 2014. Kawai Vivian K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
International warfarin genotype-guided dosing algorithms in the Turkish population and their preventive effects on major and life-threatening hemorrhagic events. Pharmacogenomics. 2015. Karaca Sefayet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic considerations in the treatment of gout. Pharmacogenomics. 2015. Roberts Rebecca L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Population pharmacogenetics of Ibero-Latinoamerican populations (MESTIFAR 2014). Pharmacogenomics. 2015. Sosa-Macias Martha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics. 2015. You Joyce H S. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Validation of warfarin pharmacogenetic algorithms in 586 Han Chinese patients. Pharmacogenomics. 2015. Peng Qi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. PloS one. 2015. Pengo Vittorio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparison of Nine Statistical Model Based Warfarin Pharmacogenetic Dosing Algorithms Using the Racially Diverse International Warfarin Pharmacogenetic Consortium Cohort Database. PloS one. 2015. Liu Rong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Warfarin dosage response related pharmacogenetics in chinese population. PloS one. 2015. Li Siyue, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Novel single nucleotide polymorphism in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans. Translational research : the journal of laboratory and clinical medicine. 2014. Hernandez Wenndy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: it matters if you're black or white. Blood. 2014. Wadelius Mia. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. European journal of clinical pharmacology. 2014. Snyder Ben D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis. Journal of Korean medical science. 2014. Lee Ji Eun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. Journal of clinical pharmacology. 2014. Li Xi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH. 2014. Franchini M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. Puerto Rico health sciences journal. 2014. Valentín Isa I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics role in the safety of acenocoumarol therapy. Thrombosis and haemostasis. 2014. Jiménez-Varo E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics. Trends in cardiovascular medicine. 2014. Johnson Julie A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing. Clinical pharmacology and therapeutics. 2014. Caudle Kelly E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA : the journal of the American Medical Association. 2014. Chung Wen-Hung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. Journal of clinical pharmacology. 2014. Robertson Sarah M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm. Pharmacogenetics and genomics. 2014. Jiménez-Varo Enrique, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Relationship between the CYP2C9 IVS8-109A>T polymorphism and high losartan hydroxylation in healthy Ecuadorian volunteers. Pharmacogenomics. 2014. Dorado Pedro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Characterizing variability in warfarin dose requirements in children using modelling and simulation. British journal of clinical pharmacology. 2014. Hamberg Anna-Karin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population. Pharmacogenomics. 2014. Giri Anil K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. The pharmacogenomics journal. 2014. Jeong E, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. The pharmacogenomics journal. 2014. Hawcutt D B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: A potential role of CYP4F2 and GGCX polymorphisms. Thrombosis research. 2014. Wypasek Ewa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. British journal of haematology. 2014. Vear Susan I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity. Clinical pharmacology and therapeutics. 2014. Roustit M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves. Journal of clinical pharmacy and therapeutics. 2014. An S H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An atlas of genetic influences on human blood metabolites. Nature genetics. 2014. Shin So-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Pediatric blood & cancer. 2014. Shaw Kaitlyn, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 2014. Brown Andrew Mk, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches. Pharmacogenomics. 2014. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014. Mizzi Clint, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics, Plasma Concentrations, Clinical Signs and EEG during Propofol Treatment. Basic & clinical pharmacology & toxicology. 2014. Khan Muhammad Suleman, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics. 2014. Cerezo-Manchado Juan Jose, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics. 2014. Lee Yee Ming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis. Thrombosis research. 2014. De Tanima, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. Basic & clinical pharmacology & toxicology. 2014. Botton Mariana R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics of platelet inhibitor treatment. British journal of clinical pharmacology. 2014. Trenk Dietmar, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. British journal of clinical pharmacology. 2014. Verhoef Talitha I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 Gene Variants, Race, and Mortality Among Clopidogrel Treated Patients Following Acute Myocardial Infarction. Circulation. Cardiovascular genetics. 2014. Cresci Sharon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prioritizing genomic applications for action by level of evidence: a horizon-scanning method. Clinical pharmacology and therapeutics. 2014. Dotson W D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients. European journal of clinical pharmacology. 2014. Klen Jasna, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: influence on quality of long-term anticoagulation. Pharmacological reports : PR. 2014. Nahar Risha, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Adoption of a clinical pharmacogenomics implementation program during outpatient care-initial results of the University of Chicago "1,200 Patients Project". American journal of medical genetics. Part C, Seminars in medical genetics. 2014. O'Donnell Peter H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. British journal of clinical pharmacology. 2014. Ke Alice Ban, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers. Clinical pharmacology and therapeutics. 2014. Markert C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. Clinical pharmacology and therapeutics. 2014. Perera M A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Improved accuracy of anticoagulant dose prediction using a pharmacogenetic and artificial neural network-based method. European journal of clinical pharmacology. 2014. Isma'eel Hussain A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. The pharmacogenomics journal. 2014. Gassó P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacoepidemiologic and in Vitro Evaluation of Potential Drug-Drug Interactions of Sulfonylureas with Fibrates and Statins. British journal of clinical pharmacology. 2014. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic Risk Factors for Major Bleeding in Warfarin Patients in a Community Setting. Clinical pharmacology and therapeutics. 2014. Roth Joshua A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2014. Lowenberg Daniella, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenetics and genomics. 2014. Lee Hye-In, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014. Polimanti Renato, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based warfarin dosing in children. Pharmacogenomics. 2014. Hamberg Anna-Karin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. European journal of clinical pharmacology. 2014. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of optimal warfarin maintenance dose using advanced artificial neural networks. Pharmacogenomics. 2014. Grossi Enzo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2C9*2 With Bosentan-Induced Liver Injury. Clinical pharmacology and therapeutics. 2013. Markova S M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. Genetic testing and molecular biomarkers. 2013. Liang Yundan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin. Indian journal of pharmacology. 2014. Karnik Niteen D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Characterization of a novel CYP2C9 mutation (1009C>A) detected in a warfarin-sensitive patient. Journal of pharmacological sciences. 2014. Luo Shun-Bin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of genetic factors on the effect of additional loading doses and two maintenance doses used to overcome clopidogrel hyporesponsiveness. Medicina (Kaunas, Lithuania). 2014. Latkovskis Gustavs, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A pharmacogenetics-based warfarin maintenance dosing algorithm from northern chinese patients. PloS one. 2014. Chen Jinxing, et al. PubMed